News Search Results
Mar 02, 2026, 17:00 ET Congruence and Ono Pharma Expand Multi-Target Research Partnership with the Addition of Two New Programs
readily scalable and repeatable value creation paradigm.About Congruence TherapeuticsCongruence is a computationally driven biotechnology company building a unique pipeline of transformative small molecule correctors rationally designed to rescue aberrant protein function. Our proprietary
More news about: Congruence Therapeutics
Mar 02, 2026, 16:05 ET Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights
CARLSBAD, Calif., March 2, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,
More news about: Tyra Biosciences
Mar 02, 2026, 14:32 ET Cognizin® Citicoline Powers Happy Panda™'s New Functional Energy Drink Launch
for retail expansion to follow.About Kyowa Hakko USAKyowa Hakko USA is a subsidiary of Kyowa Hakko Bio Co., Ltd., a global biotechnology company with over 75 years of expertise in fermentation, purification, and modification of bioactive substances. Kyowa Hakko Bio is dedicated to
More news about: Kyowa Hakko U.S.A
Mar 02, 2026, 12:15 ET Peli BioThermal Announces Strategic Partnership with Polar Group in Brazil
Through this collaboration, Polar Group will provide sales and leasing support for Peli BioThermal solutions, giving pharmaceutical, biotechnology and healthcare organizations in Brazil access to proven temperature-controlled packaging backed by in-region expertise.Brazil represents
More news about: Peli BioThermal
Mar 02, 2026, 12:15 ET Peli BioThermal Announces Strategic Partnership with Polar Group in Brazil
Through this collaboration, Polar Group will provide sales and leasing support for Peli BioThermal solutions, giving pharmaceutical, biotechnology and healthcare organizations in Brazil access to proven temperature-controlled packaging backed by in-region expertise.Brazil represents
More news about: Peli BioThermal
Mar 02, 2026, 11:45 ET uniQure N.V. (QURE) Class Action Lawsuit Filed by Kessler Topaz Meltzer & Check, LLP: Investors Face March 13, 2026, Deadline
(short video)UNIQURE N.V. CLASS ACTION LAWSUIT - COMPLAINT ALLEGATION SUMMARY:uniQure is a biotechnology company developing gene therapies for rare diseases, including Huntington's disease (HD). uniQure's leading drug candidate is AMT-130, a novel gene
More news about: Kessler Topaz Meltzer & Check, LLP
Mar 02, 2026, 10:31 ET Skyhawk Announces Australia's Therapeutic Goods Administration Has Determined SKY-0515 for Huntington's Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway
BOSTON, March 2, 2026 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets for a series of challenging neurological diseases, announces
More news about: Skyhawk Therapeutics
Mar 02, 2026, 10:31 ET Microfluidics Market to Reach $77.5 Billion, Globally, by 2033 at 13.7% CAGR: Allied Market Research
integration have attracted pharmaceutical companies and research institutions seeking efficient and scalable analytical tools. The expansion of biotechnology research facilities and diagnostic laboratories equipped with advanced analytical capabilities has further supported market growth. In addition,
More news about: Allied Market Research
Mar 02, 2026, 10:30 ET Cresilon Receives Innovative Technology Contract from Vizient for TRAUMAGEL
Vizient may award a contract outside of the competitive bid cycle.About Cresilon Cresilon® is a Brooklyn-based biotechnology company that develops, manufactures, and markets hemostatic medical devices utilizing the company's proprietary hydrogel technology. The company's
More news about: Cresilon
Mar 02, 2026, 10:29 ET XtalPi's AI + Robotics Platform Powers First Clinical Milestone for ReviR's Rare Neurological Drug RTX-117
in expanding treatment options for underserved patient populations.About ReviR TherapeuticsReviR Therapeutics is a global biotechnology company committed to discovering and developing innovative therapies for patients with serious genetic diseases. ReviR was founded in 2021 by leaders
More news about: XtalPi
Mar 02, 2026, 10:22 ET Skyhawk Announces Australia's Therapeutic Goods Administration Has Determined SKY-0515 for Huntington's Disease Meets Eligibility Criteria for Registration via the Provisional Approval Pathway
BOSTON, March 2, 2026 /PRNewswire/ -- Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets for a series of challenging neurological diseases, announces
More news about: Skyhawk Therapeutics
Mar 02, 2026, 09:13 ET National Survey: Veterinary Professionals See Stem Cell Therapy as a Powerful New Tool for Inflammatory Diseases in Pets
inflammatory diseases in pets. The survey, conducted by the American Animal Hospital Association (AAHA) in collaboration with Gallant, an animal health biotechnology company advancing ready-to-use stem cell therapies for pets, gathered responses from more than 1,000 veterinary professionals to examine perspectives
More news about: Gallant
Mar 02, 2026, 09:10 ET Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will host its 2026 Annual Meeting of Stockholders (the "Meeting")
More news about: Anixa Biosciences, Inc.
Mar 02, 2026, 09:00 ET Flare Therapeutics Inc. Partners with Simplicis to Eliminate "Single-Point-of-Failure" Risks in Compound Management
solution tailored to meet the evolving needs of the biotechnology and pharmaceutical sectors, delivering efficiency and scalability for research organizations worldwide.About Flare TherapeuticsFlare Therapeutics is a biotechnology company opening up a new therapeutic space with a novel
More news about: Simplicis
Mar 02, 2026, 09:00 ET ReviR Therapeutics Announces First Participant Dosed in Phase 1 Study and Secures CDE Clearance for Two Orphan Indications in China, Supporting Future U.S. Expansion Strategy
SAN FRANCISCO and SHANGHAI, March 2, 2026 /PRNewswire/ -- ReviR Therapeutics, a clinical-stage biotechnology company pioneering AI-driven RNA-modulating small molecules to treat rare and genetic diseases, today announced a pivotal clinical and dual regulatory
More news about: ReviR Therapeutics
Mar 02, 2026, 08:35 ET Halia Therapeutics Announces Presentation at the BIO Investment & Growth Summit
a differentiated strategy versus blocking individual downstream cytokines.About Halia TherapeuticsHalia Therapeutics is a biotechnology company developing first-in-class inflammasome inhibitors. We target the root causes of inflammation-driven diseases to create transformative therapies.Media
More news about: Halia Therapeutics
Mar 02, 2026, 08:35 ET Halia Therapeutics Announces Presentation at the BIO Investment & Growth Summit
a differentiated strategy versus blocking individual downstream cytokines.About Halia TherapeuticsHalia Therapeutics is a biotechnology company developing first-in-class inflammasome inhibitors. We target the root causes of inflammation-driven diseases to create transformative therapies.Media
More news about: Halia Therapeutics
Mar 02, 2026, 08:00 ET Efor strengthens its North American presence with the acquisition of DynamixE
its expertise in Commissioning, Qualification & Validation (CQV), process engineering, automation and digitalization for pharmaceutical and biotechnology industries.
More news about: Efor
Mar 02, 2026, 07:05 ET REGENXBIO to Participate in Upcoming Investor Conferences
replays of the webcasts will be available for approximately 30 days following the events.ABOUT REGENXBIO Inc.REGENXBIO is a biotechnology company on a mission to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the field
More news about: REGENXBIO Inc.
Mar 02, 2026, 07:00 ET Matricelf Named Most Innovative Company of 2026 at Advanced Therapies Week in San Diego
SAN DIEGO and NESS ZIONA, Israel, March 2, 2026 /PRNewswire/ -- Matricelf Ltd. (TASE: MTLF), a biotechnology company developing personalized regenerative therapies, today announced that it was awarded 1st place at the prestigious Innovation Exchange Award
More news about: Matricelf Ltd.
Mar 02, 2026, 07:00 ET Lynk Pharmaceuticals Announces Positive Phase III Topline Data of Zemprocitinib in Moderate-to-Severe Atopic Dermatitis
inflammation-related signaling pathways mediated by JAK1.About Lynk PharmaceuticalsLynk Pharmaceuticals is a clinical-stage biotechnology company founded by senior drug R&D leaders and executives from Pfizer, Merck, and Johnson & Johnson. The company is dedicated to the discovery
More news about: Lynk Pharmaceuticals Co., Ltd.
Mar 02, 2026, 06:00 ET Argo Biopharma Appoints Dr. Gena Wang as Chief Financial Officer and Chief Strategy Officer
Mid-Cap Biotechnology at Barclays, where she established and led the therapeutic teams. Prior to Barclays, Dr. Wang was sell-side analyst at several leading investment banks, including Jefferies and Leerink Partners. Over the course of her career, Dr. Wang has covered a broad range of biotechnology companies
More news about: Argo Biopharmaceutical Co., Ltd
Feb 27, 2026, 20:00 ET U.S. Food and Drug Administration Approves BioMarin's PALYNZIQ® (pegvaliase-pqpz) for Adolescents 12 Years of Age and Older with Phenylketonuria (PKU)
Prescribing Information, including Boxed Warning.About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
Feb 27, 2026, 16:30 ET FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time
/PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver for its LPT-CBD
More news about: Innocan Pharma Corporation
Feb 27, 2026, 16:30 ET FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time
2026 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver for its LPT-CBD
More news about: Innocan Pharma Corporation